What Moventig Treats: Main Uses and Benefits

Moventig is commonly used to help with the management of Opioid-Induced Constipation (OIC) in adult patients who are on continuous opioid pain relief for chronic non-cancer pain. The medication is applied in situations involving persistent symptoms where additional supportive management may be appropriate, specifically across domains where symptomatic support is needed in clinical settings involving functional stress caused by continuous treatment.

---

Treatment for Chronic Opioid-Induced Constipation (OIC)

This medication is relevant for managing conditions characterized by periods of heightened symptoms related to long-term opioid use. It is generally used when patients experience chronic, persistent bowel dysfunction that directly interferes with daily functioning due to the continuous nature of their pain therapy. The medication is applied in addressing symptoms related to OIC, which may involve manifestations such as infrequent bowel movements, straining during defecation, the passage of hard or dry stools, and the feeling of incomplete evacuation. This treatment may be part of symptomatic management during phases when symptoms become more noticeable and short-term symptom stabilization is important.

---

Relief of Persistent, Disruptive Bowel Symptoms

The medication is used for managing symptom clusters that may become intense or disruptive. By intervening in this symptom cluster, Moventig may assist with increasing the frequency of spontaneous bowel movements (SBMs), and provides supportive relief when symptoms interfere with routine activities. This contributes to easing the overall symptom load and supports patients during episodes of heightened discomfort.

---

Quick Fact: Relief for Opioid-Induced Constipation This medication is generally used to help address symptoms related to functional stability issues, primarily targeting adult patients experiencing persistent bowel dysfunction while on stable, long-term opioid regimens.

Moventig is intended for adult patients (ge 18 years of age) who are on continuous opioid therapy for chronic non-cancer pain, and for whom laxative treatment has been inadequate. Official regulatory labeling strictly defines who can and cannot use the medicine, primarily based on potential risks related to gastrointestinal health and drug metabolism.

---

Contraindicated Populations (Must Not Use)

Classification	Rule
GI Obstruction Risk	Patients with known or suspected gastrointestinal (GI) obstruction or at increased risk of recurrent obstruction.
Drug Interactions	Patients concomitantly using strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir).
Hypersensitivity	Patients with a known serious or severe hypersensitivity reaction to naloxegol or any excipients.

---

Eligibility Restrictions and Special Considerations

Eligibility is limited or conditional for certain groups:

• Age-Related: Safety and efficacy have not yet been established for the pediatric population (lt 18 years). No dose change is recommended for older adults (ge 65 years).
• Organ Function: Use is not recommended in patients with severe hepatic impairment. A special initial approach is required for patients with moderate or severe renal insufficiency.
• Reproductive Status: Use is not recommended during pregnancy or lactation due to the potential risk of opioid withdrawal in the fetus or nursing infant.

Interactions with other medicines and products

The official interaction profile for naloxegol is primarily defined by pharmacokinetic interactions involving the Cytochrome P450 3A4 (CYP3A4) enzyme, which is the primary system for the drug's metabolic clearance. This forms the basis for multiple official restrictions.

Co-administration with strong CYP3A4 inhibitors (such as clarithromycin or ketoconazole) is strictly contraindicated. This prohibition is due to the potential for these medicines to cause a significant, multi-fold increase in naloxegol systemic exposure, thereby risking the precipitation of opioid withdrawal symptoms.

Regulatory documents also advise against the use of moderate CYP3A4 inhibitors (e.g., diltiazem) and strong CYP3A4 inducers (e.g., rifampin). Inducers are not recommended because they substantially decrease naloxegol exposure, which may result in reduced efficacy. Consumption of Grapefruit or Grapefruit Juice must be avoided, as this food product is classified as a CYP3A4 inhibitor that increases systemic levels of naloxegol.

Due to the drug's action as a mu-opioid receptor antagonist, co-administration with other opioid antagonists is generally avoided to prevent additive pharmacodynamic effects. Use is not recommended in patients with severe hepatic impairment, as the appropriate exposure management in this population has not been determined.

How Moventig Works: The Mechanism of Action

Moventig's mechanism centers on the competitive blockade of the mu-opioid receptor (MOR), the primary molecular target. This interaction occurs selectively on MORs located in the gastrointestinal (GI) tract, specifically within the Enteric Nervous System (ENS). By binding to these receptors, the drug removes the inhibitory signal exerted by opioid molecules on the gut's neural activity.

This action is strictly peripheral, a consequence of the molecule's PEGylation and its status as a substrate for the P-glycoprotein (P-gp) efflux pump. This engineered Central Nervous System (CNS) sparing mechanism ensures the preservation of MOR activation in the brain and spinal cord.

The consequence of peripheral antagonism is the restoration of ENS function. This lifts the brake on the gut’s normal muscle contractions (peristalsis) and reverses the opioid-induced decrease in intestinal fluid secretion. The resulting physiological change is the acceleration of gastrointestinal transit time and modulation of luminal content.

How to Use Moventig: Administration Guidelines

Moventig (naloxegol) is a medicine taken once daily (OD) via the oral route. The high-level administration principles define the required dosing, timing, and patient-specific adjustments.

---

Administration Scope

Feature	Instruction Summary
Standard Dosing	The typical starting and maintenance dose is 25 mg once daily. A lower dose of 12.5 mg once daily is used if the higher dose is not tolerated.
Timing in Relation to Meals	The tablet must be taken on an empty stomach. This means consuming the dose at least 30 minutes before or two hours after the first meal of the day. The consumption of grapefruit or grapefruit juice is restricted during treatment.
Handling and Preparation	The tablet is intended to be swallowed whole and should not be crushed, cut, or chewed. If necessary, it may be crushed and mixed with water (120 ml) for immediate oral consumption or administration via a nasogastric tube.
Dose Adjustments	A starting dose of 12.5 mg once daily is indicated for patients with moderate or severe renal impairment or those taking moderate CYP3A4 inhibitors.

---

Procedural Context

Treatment is intended to continue for the duration of the patient's continuous opioid therapy and must be discontinued if the opioid treatment itself is stopped. Before initiating Moventig, maintenance laxative therapy should be stopped; however, laxatives may be resumed if an adequate response is not achieved after three days. If a dose is missed, it should be taken as soon as remembered, unless it is close to the next scheduled dose (e.g., within 12 hours), in which case the missed dose should be skipped. The standard administration protocol is built around adherence to the once-daily schedule under the precise fasting condition.

Research evidence / Overview of studies for Moventig

Evidence for Opioid-Induced Constipation (OIC) in Adults

Moventig was studied in several large-scale, controlled clinical trials as part of its clinical evaluation. The foundation of the evidence comes from two principal intermediate-term (12-week) randomized, double-blind, placebo-controlled Phase 3 trials which were used in research exploring how symptoms change over time in the study populations.

Researchers studied adults on stable, long-term opioid therapy for chronic non-cancer pain, focusing particularly on individuals whose condition was characterized by functional limitations and who had not achieved an adequate response from previous laxative use. The research examined the association between the tested doses and the frequency of bowel movements compared to a placebo. Findings describe patterns observed in the studies related to the reporting of sustained SBM responder status when compared to the placebo group.

Primary Outcomes Measured in Clinical Trials

Studies monitored outcomes related to physical discomfort. The main outcome metric focused on the proportion of responders, which required a consistent, sustained level of weekly Spontaneous Bowel Movements (SBMs) over the 12-week study interval. This measure was used in research examining symptom intensity or variability to determine patterns of symptomatic change.

Studies also examined the time interval until the occurrence of the first SBM after dosing. Findings indicate patterns related to the measured time interval until the first SBM was reported when compared to the placebo. Furthermore, studies explored changes measured during the study period related to constipation symptoms, such as straining and stool consistency, with research providing insight into short-term changes in these areas.

Long-Term Research and Durability of Observation

The primary, comparative efficacy research that supported the medicine's evaluation focused on the 12-week treatment period. Follow-up durations were limited for the initial comparative efficacy studies. Researchers conducted open-label extension studies for a longer period (up to 52 weeks) that were primarily designed to observe continued patient experience. Findings describe patterns observed in the studies showing continued monitoring of symptom measurement changes over the extended observation intervals.

Key Limitations and Remaining Uncertainties

The core research is confined to the chronic non-cancer pain population, and the duration of the primary efficacy assessment was limited to 12 weeks. Comparative evidence versus other established therapeutic approaches for OIC is also an area where data are still emerging, as the primary trials focused on comparison with a placebo.

Key Studies & References

1. Naloxegol for treating opioid-induced constipation (NICE Technology Appraisal Guidance TA345)

Common questions about Moventig (FAQ)

Q: How quickly should I expect to feel the effects of Moventig?

Official product information notes that studies examined the time until patients had their first spontaneous bowel movement (SBM) after starting the first dose. These studies provided data on the timeframe observed for the first bowel movement after starting treatment compared to the placebo.

---

Q: Is it normal to feel a bit nauseous when first starting Moventig?

According to the official product information, nausea is listed as a common side effect of Moventig. The majority of gastrointestinal side effects observed in clinical studies were generally described as mild to moderate. These effects typically occurred early in the treatment and often improved with continued use.

---

Q: Is Moventig the same as other constipation medicines, or does it work differently?

Moventig is in a different class of medicine called a 'Peripherally Acting Mu-Opioid Receptor Antagonist' (PAMORA). Unlike many traditional laxatives, it works by blocking the negative effects that opioid medications have specifically on the opioid receptors in the gut. This peripheral action is designed to counteract the effect of opioids on the bowel's natural movement.

---

Q: Are there any dietary restrictions or foods to avoid while on Moventig?

Yes, official regulatory documents advise that grapefruit or grapefruit juice must be avoided while taking this medication. This restriction is important because grapefruit can significantly increase the drug's exposure in the body.

---

Q: Can elderly patients safely take Moventig?

Official information indicates that no dose change is generally recommended for older adults (65 years and older) unless they have moderate or severe kidney impairment. Clinical studies did not identify overall differences in safety or effectiveness when comparing older adult patients to younger patients.

---

Q: What is the longest someone has been on Moventig, according to studies?

The primary efficacy studies used to approve the drug lasted 12 weeks. Following this, open-label extension studies were conducted for a longer period, with observation intervals extending up to 52 weeks (one year), to continue monitoring patient experience.

---

Q: If I stop taking opioids, do I still need to take Moventig?

Official administration guidelines state that treatment with Moventig should be discontinued if the opioid treatment itself is stopped. The medication is intended to be used only for the duration of continuous opioid therapy.

---

Q: What happens if I miss a dose of Moventig?

Regulatory guidance states that a missed dose should be taken as soon as it is remembered. However, if it is close to the next scheduled dose (e.g., within 12 hours), the missed dose should be skipped, and the next dose should be taken at the regular time.

---

Q: Can Moventig interact with blood pressure medications?

The drug’s official interaction profile is primarily defined by its breakdown through the CYP3A4 enzyme system. Patients should consult the official drug label and their healthcare provider regarding potential interactions with all co-administered medications, including blood pressure drugs.

---

Q: Is Moventig safe to use if I have a history of diverticulitis?

Moventig is contraindicated (should not be used) in patients with known or suspected gastrointestinal (GI) obstruction. Because of a risk of GI perforation, the medication should be used with caution in patients who have certain pre-existing risk factors, such as active or suspected GI lesions.

---

Q: Why do some people with OIC choose Moventig over a standard laxative?

Moventig is specifically indicated for adults with opioid-induced constipation (OIC) who have had an inadequate response to traditional laxative treatment. It is an option because it works differently by directly counteracting the effect of opioids in the gut, which is the root cause of OIC.

---

Q: What are the signs that Moventig is working as intended?

Clinical studies monitored outcomes that suggest the medication is working, such as an increase in the frequency of Spontaneous Bowel Movements (SBMs). Other signs monitored included a reduction in constipation symptoms like straining and an improvement in stool consistency.

---

Q: Is Moventig considered a stimulant laxative?

No. Moventig is officially classified as a Peripherally Acting Mu-Opioid Receptor Antagonist (PAMORA). It does not work by chemically stimulating the bowel muscles. Instead, it works by blocking the inhibitory effect that opioid medications have on natural gut movement.

---

Q: How is Moventig eliminated from the body?

According to pharmacokinetic information, Moventig is primarily broken down (metabolized) by an enzyme system in the body called CYP3A4. The resulting products are then eliminated from the body through both feces and urine.

---

Q: Can Moventig be used for constipation not related to opioid use?

No. Official regulatory documents state that Moventig is specifically indicated only for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain. It is not approved for use with general constipation.

---

Q: What should I do if I experience severe stomach pain after taking Moventig?

Due to a serious warning regarding gastrointestinal perforation, official product information advises seeking emergency medical attention immediately if severe, persistent, or worsening abdominal pain develops. This symptom requires prompt evaluation.

---

Q: What research supports the use of Moventig for chronic pain patients?

The foundation of the clinical evidence comes from two large-scale, intermediate-term (12-week) randomized, double-blind, placebo-controlled Phase 3 trials. These studies were conducted specifically in adults on stable, long-term opioid therapy for chronic non-cancer pain.

---

Q: Does Moventig come in different strengths?

Yes, according to official regulatory labeling, the film-coated tablet is available in two different strengths: 12.5 mg and 25 mg.

---

Q: Can Moventig affect sleep?

The official product label lists headache and symptoms consistent with opioid withdrawal (which can include anxiety and irritability) as common side effects. However, there is no specific listing for insomnia or somnolence (drowsiness) as a common adverse reaction.

---

Q: Can Moventig interact with herbal supplements like St. John's Wort?

Official regulatory documents advise against the use of strong CYP3A4 inducers, which are substances that speed up the body's breakdown of the drug. Since St. John's Wort is a known strong inducer of this enzyme, it is generally advised to be avoided as it could significantly reduce the effectiveness of Moventig.

---

Q: Why is Moventig not used for non-opioid related constipation?

The core mechanism of action for Moventig is to specifically block opioid molecules from binding to receptors in the gut. Since it is designed only to reverse the effects of opioids on the bowel, it is not an effective treatment for constipation caused by factors other than opioid use.

---

Q: How long does the effect of one Moventig dose last?

The medication is officially approved for a standard dosing schedule of once daily (OD). This indicates that the therapeutic effects of the dose are intended to last for approximately 24 hours to align with the daily dosing requirement.

---

Q: Does Moventig cause dependence or withdrawal effects?

The approved regulatory labeling indicates the drug has no risk of abuse or physical dependency. However, symptoms consistent with opioid withdrawal (such as chills, diarrhea, and anxiety) may occur as a serious side effect, which patients should monitor for.

How to Store and Dispose of Moventig?

The storage and disposal of Moventig must strictly follow the requirements defined in the official regulatory documentation to maintain product stability and ensure safety.

Storage Requirements:

Domain	Official Requirement
Temperature	Store below 25 C (or at room temperature, away from excess heat and moisture).
Child Safety	Keep this medicine out of the sight and reach of children.
Stability	Do not use after the expiry date (EXP) stated on the carton.
Handling	Keep in the original, tightly closed container.

Disposal Requirements:

Unused or expired Moventig must not be disposed of via household waste or wastewater. For proper disposal, consult a pharmacist regarding local requirements or drug take-back programs. If a tablet is crushed and mixed with water for administration, the resulting mixture must be consumed immediately.